Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of REGN2222 for prevention of medically attended RSV infection in preterm infants
NL-OMON45852Phase 3Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of suptavumab in respiratory syncytial virus disease (RSV) (4 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Pharmacokinetics of REGN2222 and Medically attended RSV infection. Started Jan 2016; status: active, not recruiting.
02
Drugs
suptavumab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on NL-OMON45852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45852.